PFE vs WFC: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Wells Fargo & Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
VS
Wells Fargo & Company · Financial Services
$87.53
+18.1% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
WFC has more upside to fair value
(+18.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
WFC |
| Current Price |
$25.22 |
$87.53 |
| Fair Value Estimate |
$25.92 |
$103.38 |
| Upside to Fair Value |
+2.8%
|
+18.1%
|
| Market Cap |
$143.7B |
$267.8B |
| Forward P/E |
19.2x
|
—
|
| EV / EBITDA |
12.3x
|
15.8x
|
| Price / Sales |
2.3x
|
2.1x
|
| Price / FCF |
15.2x
|
226.4x
|
| Revenue Growth YoY |
+5.4%
|
+11.3%
|
| Gross Margin |
69.3%
|
64.5%
|
| Operating Margin |
23.4%
|
21.2%
|
| Return on Equity |
8.4%
|
12.6%
|
| Dividend Yield |
0% |
2.06% |
| FCF Yield |
6.6%
|
0.44%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Wells Fargo is a diversified U.S. bank operating consumer and commercial banking, corporate and investment banking, and wealth management, supported by a large deposit franchise, a $2.3 trillion asset base, nationwide advisory distribution, and increasingly relevant capital-markets capabilities. Business quality is high but not without legacy constraints: return on equity is 12.6%, gross margin i…
Accumulation Zones
| Metric |
PFE |
WFC |
| Zone Low |
$19.44 |
$77.53 |
| Zone High |
$22.03 |
$87.87 |
| In Buy Zone? |
No
|
Yes
|